TD Cowen Lowers BioNTech (NASDAQ:BNTX) Price Target to $94.00

BioNTech (NASDAQ:BNTX) had its target price lowered by stock analysts at TD Cowen from $116.00 to $94.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the stock. TD Cowen’s price objective would suggest a potential upside of 4.33% from the company’s previous close.

Several other equities analysts have also weighed in on BNTX. Morgan Stanley cut their price target on BioNTech from $134.00 to $125.00 and set an “overweight” rating for the company in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and set a $140.00 price objective on shares of BioNTech in a research report on Thursday, December 11th. Raymond James Financial reaffirmed an “outperform” rating on shares of BioNTech in a research report on Tuesday. Bank of America reaffirmed a “buy” rating and issued a $128.00 target price on shares of BioNTech in a research report on Tuesday. Finally, BMO Capital Markets decreased their target price on BioNTech from $143.00 to $128.00 and set an “outperform” rating for the company in a report on Wednesday. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $133.73.

BioNTech Stock Performance

Shares of BNTX opened at $90.10 on Wednesday. The stock has a 50-day moving average of $106.54 and a two-hundred day moving average of $102.66. The stock has a market cap of $20.29 billion, a P/E ratio of -17.19 and a beta of 1.51. BioNTech has a one year low of $79.52 and a one year high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.54.

Hedge Funds Weigh In On BioNTech

Several hedge funds have recently added to or reduced their stakes in the business. Dodge & Cox raised its stake in BioNTech by 315.7% in the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after purchasing an additional 2,769,654 shares during the last quarter. BNP Paribas Financial Markets grew its position in BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after acquiring an additional 474,796 shares during the period. GSK plc acquired a new stake in BioNTech during the 4th quarter worth approximately $84,711,000. Franklin Resources Inc. raised its stake in shares of BioNTech by 76.8% in the 2nd quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock valued at $80,065,000 after acquiring an additional 326,556 shares during the period. Finally, Invesco Ltd. raised its position in BioNTech by 5.6% in the second quarter. Invesco Ltd. now owns 681,100 shares of the company’s stock valued at $72,517,000 after purchasing an additional 35,958 shares during the period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

More BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Canaccord reiterated a “buy” rating and set a high $171 price target, signaling strong upside relative to the current level and supporting bullish investor thesis on long‑term mRNA opportunity. Canaccord reaffirms buy, $171 PT
• Positive Sentiment: Goldman Sachs reaffirmed its “buy” rating, providing another institutional vote of confidence that may stabilize sentiment among growth‑oriented holders. Goldman Sachs reaffirms buy
• Positive Sentiment: BioNTech and its co‑founders announced plans to pursue next‑generation mRNA innovations — a strategic signal that the company is investing in future product pipelines beyond COVID vaccines. Co‑founders pursue next‑gen mRNA
• Neutral Sentiment: Independent write‑ups are debating whether recent weakness makes BNTX a value play; the analysis highlights multi‑period share declines but leaves valuation conclusions to readers. Yahoo analysis on BNTX valuation
• Neutral Sentiment: Data feeds flagged a “large increase” in short interest, but the published figures are inconsistent (zeros/NaN and 0.0 days to cover), suggesting a likely reporting glitch rather than actionable short‑squeeze pressure.
• Neutral Sentiment: BMO trimmed its price target (to $128) but kept an “outperform” stance — a modest downgrade in optimism rather than a rout. BMO lowers PT to $128
• Negative Sentiment: Several outlets reported a steep share drop after an earnings miss and leadership changes (founder departures); that combination typically triggers near‑term selling and raises execution risk. Earnings miss & founder exodus — Blockonomi Earnings miss & leadership change — Tokenist
• Negative Sentiment: Multiple sell‑side revisions trimmed expectations: Citigroup lowered its PT to $130 (still a “buy”), TD Cowen cut to $94 and moved to “hold”, and Jefferies published more cautious forecasts — collectively cooling near‑term analyst enthusiasm. Citigroup cuts PT to $130 TD Cowen cuts to $94 Jefferies lowers expectations

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.